Teva urges Fed Circuit to save skinny label law from ‘nullification’
03-12-2020
Bill Perry / Shutterstock.com
One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Hatch-Waxman Act, skinny label, generics, Federal Circuit, Apotex, Mylan, GSK, Teva, Coreg
